Red Spruce Capital LLC Boosts Holdings in Abbott Laboratories $ABT

Red Spruce Capital LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 24.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,210 shares of the healthcare product maker’s stock after acquiring an additional 7,078 shares during the period. Red Spruce Capital LLC’s holdings in Abbott Laboratories were worth $3,286,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Up 2.0%

Shares of NYSE:ABT opened at $107.86 on Friday. The firm has a fifty day moving average price of $95.06 and a two-hundred day moving average price of $99.97. The company has a market cap of $186.63 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 2.05 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Analysts Set New Price Targets

Several research analysts recently commented on ABT shares. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Raymond James Financial reduced their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Evercore decreased their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.